A Randomised, Double-Masked, Placebo-Controlled Phase 3 Study on the Efficacy and Safety of STN1013800 (Oxymetazoline HCl 0.1% Eye Drops) used twice daily (BID) in the Treatment of Acquired Blepharoptosis
Able to understand and sign an informed consent form prior to participation in any studyrelated procedures.
Male or female subjects ≥ 18 years and ≤ 75 years.
diagnosis of acquired ptosis in both eyes with MRD 1 ≥0 and ≤ 2 mm in the study eye
Snellen VA of 20/80 or better in both eyes Note: MRD1 is defined as the distance between upper eye lid margin and centre of the pupil. MRD0 is defined as the upper eye lid margin at the centre of the pupil. Measurement of MRD1 will be done by a Central Reading Centre. If the centre of the pupil cannot be determined by the Central Reading Centre due to negative MRD1, the subject will be deemed ineligible.
Congenital ptosis.
Pseudo ptosis (upper eyelid dermatochalasis that overhangs the upper eyelid margin); or
Dermatochalasis that extends less than 3 mm above the upper eyelid margin.
Neurogenic ptosis (e.g., Horner's syndrome, 3rd cranial nerve palsy).